Skip to main content
Log in

Liver Resection for Metastatic Disease After Y90 Radioembolization: A Case Series with Long-Term Follow-Up

  • Hepatobiliary Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Introduction

There are only few reports of liver resections for metastatic disease in patients previously treated with Y-90 radioembolization (RE), and long-term outcome data are sparse. We reviewed our center’s experience in patients undergoing hepatectomy after hepatic RE.

Methods

A retrospective chart review of patients undergoing RE from 2004 to 2011 was performed. Demographic, clinicopathologic, operative, and long-term outcomes variables were collected. Independent pathologic review of tumor necrosis and normal liver tissue grading of fibrosis and inflammation after resection was performed. Data are expressed as medians and ranges.

Results

RE was delivered to 106 patients with primary and metastatic disease of the liver, of whom 9 patients (6 males, 3 females, median age 54 (47–76) years) with metastatic disease ultimately underwent resection. RE was previously administered to the right liver in five, the left liver in one, and to the whole liver in three. Two patients had a second RE performed before resection. Six of the nine patients had previously received several infusions of cytotoxic therapy. The operations occurred at a median of 115 (56–245) days after RE and included right lobectomy (n = 5), left lobectomy (n = 1), left-lateral sectionectomy (n = 1), and bilobar wedge resections (n = 2). Extrahepatic sites were resected in three patients. Median blood loss was 900 (range 250–3600) ml. Grade 3 or higher complications occurred in seven cases (78 %). Follow-up was complete all nine patients. Three patients (33 %) died within 30 days of resection. All those surviving the operative period had disease recurrence (time to recurrence: 202 [range 54–315] days), and all have since died (overall survival: 584 [range 127–1230] days). Review of resected specimens demonstrated median tumor necrosis of 70 % (range 20–90 %). In nontumor-bearing liver, fibrosis grade (0–4) and inflammation score (0–4) was 2 or less in all specimens.

Conclusions

In this small cohort of highly selected and heavily pretreated patients, long-term survival in patients undergoing resection after RE appears possible, but the operations may carry substantial risks—highlighting the importance of careful patient selection for these resections. The etiology of morbidity and mortality is likely multifactorial and additional reports that include long-term outcomes will be necessary to identify more clearly the impact of RE on postoperative complications and death.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ariel IM. Radioactive isotopes for adjuvant cancer therapy. Arch Surg. 1964;89(2):244–9.

    Article  CAS  PubMed  Google Scholar 

  2. Blanchard RJ, Lafave JW, Young SM, Frye CS, Ritchie WP, Perry JF. Treatment of patients with advanced cancer utilizing Y90 microspheres. Cancer. 1965;18:375–80.

    Article  CAS  PubMed  Google Scholar 

  3. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30(5):969–77.

    CAS  PubMed Central  PubMed  Google Scholar 

  4. Gil-Alzugaray B, Chopitea A, Inarrairaegui M, et al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. 2013;57:1078–87.

    Article  CAS  PubMed  Google Scholar 

  5. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J. 2010;16:163–75.

    Article  CAS  PubMed  Google Scholar 

  6. Gray B, Van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastasis from primary large bowel cancer. Ann Oncol. 2001;12:1711–20.

    Article  CAS  PubMed  Google Scholar 

  7. Van Hazel G, Blackwell A, Anderson J. et al, Randomised phase II trial of SIR-spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin alone in advanced colorectal cancer. J Surg Oncol. 2004;88:78–85.

    Article  PubMed  Google Scholar 

  8. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with Yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28:3687–94.

    Article  CAS  PubMed  Google Scholar 

  9. Cosimelli M, Golfieri R, Cagol PP, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103:324–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2009;138:52–64.

    Article  PubMed  Google Scholar 

  11. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920–8.

    Article  CAS  PubMed  Google Scholar 

  12. Kulik LM, Atassi B, Van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA, and bridge to transplantation. J Surg Oncol. 2006;94:572–86.

    Article  CAS  PubMed  Google Scholar 

  13. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastasis using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271–9.

    Article  PubMed  Google Scholar 

  14. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastasis. Cancer. 2008;113:921–9.

    Article  PubMed  Google Scholar 

  15. Rhee TK, Lewandowski RJ, Liu DM, et al. 90YRadioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029–35.

    Article  PubMed  Google Scholar 

  16. Bester L, Feitelson S, Milner B, Chua TC, Morris DL. Impact of prior hepatectomy on the safety and efficacy of radioembolization with Yttrium-90 microspheres for patients with unresectable liver tumors. Am J Clin Oncol. 2013. doi:10.1097/COC.0b013e31827deea1.

  17. Sharma RJ, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using Yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25:1099–106.

    Article  CAS  PubMed  Google Scholar 

  18. Inarrairaegui M, Pardo F, Bilbao JI, et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. EJSO. 2012;38:594–601.

    Article  CAS  PubMed  Google Scholar 

  19. Whitney R, Tatum C, Hahl M, et al. Safety of hepatic resection in metastatic disease to the liver after Yttrium-90 Therapy. J Surg Res. 2011;166:236–40.

    Article  PubMed  Google Scholar 

  20. Gulec SA, Pennington K, Hall M, Fong Y. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol. 2009;7:1–6.

    Article  Google Scholar 

  21. Wang LM, Jani AR, Hill EJ, Sharma RA. Anatomic basis and histopathological changes resulting from selective internal radiotherapy for liver metastasis. J Clin Pathol. 2013;66:205–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995;19:1409–17.

    Article  CAS  PubMed  Google Scholar 

  23. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastasis. J Clin Oncol. 2006;24:2065–72.

    Article  CAS  PubMed  Google Scholar 

  25. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastasis: a critical appraisal of 48 cases. Ann Surg. 2010;251:910–6.

    Article  PubMed  Google Scholar 

  26. Nosher JL, Ohman-Srickland PA, Jabbour S, Narra V, Nosher B. Changes in liver and spleen volumes and liver function after radioembolization with Yttrium-90 resin microspheres. J Vasc Interv Radiol. 2011;22:1706–13.

    Article  PubMed  Google Scholar 

  27. Ahmadzadehfar H, Meyer C, Ezziddin S, et al. Hepatic volume changes induced by radioembolization with 90 Y resin microspheres. A single center study. Eur J Nucl Med Mol Imaging. 2013;40:80–90.

    Article  PubMed  Google Scholar 

  28. Edeline J, Lenoir L, Boudjema K, et al. Volumetric changes after 90Y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20:2518–25.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Leonard R. Henry MD, FACS.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Henry, L.R., Hostetter, R.B., Ressler, B. et al. Liver Resection for Metastatic Disease After Y90 Radioembolization: A Case Series with Long-Term Follow-Up. Ann Surg Oncol 22, 467–474 (2015). https://doi.org/10.1245/s10434-014-4012-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4012-z

Keywords

Navigation